The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when ...

Adjuvant BCG therapy of superficial bladder cancer remains the most successful immunotherapy for ... intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

ImmunityBio is seeking an urgent meeting with U.S. health regulators after its bladder-cancer treatment application was rejected. The immunotherapy company said Monday that it received a ...